Recent Updates
Recently added Catalysts

Dyne Therapeutics, Inc.

DYNFDA catalysts, PDUFA dates & pipeline intelligence
$16.02
▼ -0.68 · -4.07%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full DYN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $14.0052W HIGH $27.30
Volume
2.06 M
Value Traded
33.28 M
Short % Float
15.84%
Days to Cover
10.8
-10.95%Week
+5.19%1 Month
-40.18%3 Month
-8.77%6 Month
-3.93%5 Year
-23.11%All Time

Cash Data

Unlock DYN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.00 B
EPS (TTM)
-3.23
P/E Ratio
-
Ent. Value
2.07 B
Total Shares
187.33 M
Float Shares
153.86 M
Insiders
17.89%
Institutions
88.89%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251)
Duchenne muscular dystrophy amenable to exon 51 skipping
BreakthroughPriorityFast Track+3
PDUFARNA-Based TherapiesNeurology
Unlock every DYN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

DYN Catalyst Timeline

Dated clinical, regulatory and corporate events for Dyne Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Dyne Therapeutics, Inc.

314Total events
27Upcoming
60Tier-1 (high impact)
2020 to 2028Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
T1Topline Readout
Subscribe to view catalyst details
DYNE-101Filed

Event history 50

●Quarterly UpdateCorporate
Dyne Therapeutics reports third quarter 2026 financial results
●Poster PresentationDYNE-101FiledPresentation
Poster presentation at AANEM available September 30, 2026
Myotonic Dystrophy Type 1 (DM1)source ↗
▲Oral PresentationDYNE-101FiledPresentation
Oral presentation of long-term functional improvement data at WMS
Myotonic Dystrophy Type 1 (DM1)source ↗
◆Timing GuidanceDYNE-101FiledPresentation
Disclosure of mean baseline video hand opening time (vHOT) in ACHIEVE registrational expansion cohort
Myotonic Dystrophy Type 1 (DM1)source ↗
●Quarterly UpdateCorporate
Reported Q2 2026 financial results
▲IND ClearanceDYNE-302IND
FDA clearance of IND for DYNE-302
facioscapulohumeral muscular dystrophy (FSHD)source ↗
◆Trial InitiationDYNE-302Trial
Initiation of Phase 1 clinical trial for DYNE-302 in FSHD
facioscapulohumeral muscular dystrophy (FSHD)source ↗
▼Equity OfferingCorporate
Pricing of upsized $375 million public offering of common stock
▲BLA SubmissionDYNE-251FiledRegulatory Filing
BLA submission for z-rostudirsen accepted by FDA
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲FDA Filing AcceptedDYNE-251FiledRegulatory Filing
FDA accepted BLA for z-rostudirsen with Priority Review
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
Unlock the full DYN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How DYN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30zeleciment basivarsen (z-basivarsen, DYNE-101) Phase 1/2 data presentation Phase 1/2
Unlock 10 more DYN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 20%
Small Cap
(rank 146 of 725)
Percentile Rank
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Zeleciment rostudirsen RNA-Based TherapiesNCT05524883Duchenne Muscular Dystrophy (DMD)NDA/BLA ACTIVE NOT_RECRUITING 176Sep 1, 2031
Zeleciment basivarsen RNA-Based TherapiesNCT05481879Myotonic Dystrophy Type 1 (DM1)Phase 3 ACTIVE NOT_RECRUITING 277Jul 1, 2029
Unlock the DYN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every DYN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
z-basivarsen
BreakthroughFast TrackOrphan
myotonic dystrophy type 1 (DM1)Phase 1/22026-09-29mean baseline vHOT in the ACHIEVE REC is 8.3 seconds; functional improvement across multiple measures compared to baseline, versus placebo and versus a matched natural history cohortRead MoreDyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)Read More
Scroll for more · summaries link to the source press release
Unlock every DYN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock DYN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Lucera ErickOfficer (Chief Financial Officer)Sell -1,991 117,775 held$16.82 11/13/2026
Unlock the full DYN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
TCG Crossover Management, LLC 2.1 % (-16 %) 74.35 M 4.62 M
Unlock every fund holding DYN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in DYN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see DYN ownership
Insider and institutional ownership, quarter by quarter.

DYN Short Interest

Shares sold short, counted twice a month.

15.84%
Short % of Float
of tradable shares sold short
24.4M
Shares Sold Short
-4.3% vs prior count
10.8 Very high
Days to Cover
trading days of normal volume to buy every short share back
2.3M
Avg Daily Volume
the average used for days to cover
Unlock DYN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock DYN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live DYN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock DYN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How DYN ranks across every disease it competes in

Competitive Position is a premium feature
See how DYN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

DYN News

DYN
Nov 11, 2026
DYNConferences/Events

Dyne Therapeutics to Participate in Upcoming Investor Conference

Dyne Therapeutics will participate in the Jefferies Global Healthcare Conference on November 16, 2026. The event includes a fireside chat scheduled for 2:30 p.m. GMT. A live webcast will be available on the company's website, with a replay accessible for 90 days.

Read more →
DYN
Nov 5, 2026
DYNFDA Updates
▼ -6.4%on this news

Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics reported its Q3 2026 financial results, highlighting a BLA for z-rostudirsen under FDA priority review with a target action date of January 21, 2027. The company also presented positive data from the Phase 1/2 ACHIEVE trial for z-basivarsen. Despite a net loss of $193.6 million, Dyne maintains a strong cash position of $1.134 billion.

Read more →
DYN
Oct 22, 2026
DYNGeneral

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics announced the granting of inducement equity awards to 16 new employees under Nasdaq Listing Rule 5635(c)(4). The awards include stock options for 290,100 shares and restricted stock units for 92,300 shares, with vesting schedules tied to continued employment. This move aims to enhance recruitment and retention of talent.

Read more →
DYN
Sep 29, 2026
DYNPhases

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics has released additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1). The data indicate significant functional improvements across various measures compared to baseline and placebo. Dyne anticipates topline results from the registrational expansion cohort in Q1 2027, aiming for U.S. Accelerated Approval by Q3 2027.

Read more →
DYN
Sep 8, 2026
DYNConferences/Events
▼ -16.4%on this news

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen for myotonic dystrophy type 1 (DM1) at two upcoming medical meetings. The presentations will include data from a pooled dose group and safety updates. Topline data from the registrational expansion cohort is anticipated in Q1 2027.

Read more →
DYN
Sep 3, 2026
DYNConferences/Events

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

Dyne Therapeutics announced the presentation of preclinical data for four investigational therapies targeting Duchenne Muscular Dystrophy (DMD) at the upcoming NMSG Scientific Meeting. The therapies, DYNE-253, DYNE-245, DYNE-244, and DYNE-255, aim to address specific exon mutations and are advancing into IND-enabling studies. The data supports the effectiveness of the FORCE™ platform in delivering therapeutic payloads.

Read more →
DYN
Sep 2, 2026
DYNConferences/Events

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics has announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference. These events will feature fireside chats with management, aimed at discussing the company's advancements in therapeutics for genetically driven neuromuscular diseases. Webcasts of the chats will be available on the company's website.

Read more →
DYN
Jul 29, 2026
DYNFDA Updates

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical programs. The FDA accepted the Biologics License Application for z-rostudirsen, granting Priority Review with a target action date set for January 2027. Additionally, the company completed enrollment in the Phase 1/2 ACHIEVE trial for z-basivarsen and received IND clearance for DYNE-302. Despite a net loss increase, Dyne expects to maintain a strong cash runway into Q2 2028.

Read more →
DYN
Jul 28, 2026
DYNPhases

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Dyne Therapeutics has received FDA clearance for its IND application to initiate a Phase 1 clinical trial for DYNE-302, targeting facioscapulohumeral muscular dystrophy (FSHD). This investigational drug aims to suppress DUX4 expression, which is implicated in FSHD pathogenesis. The trial will primarily assess safety and tolerability, with additional evaluations of pharmacokinetics and pharmacodynamics.

Read more →
DYN
Jul 23, 2026
DYNGeneral

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics has successfully closed an upsized public offering of 21,045,000 shares at $20.50 each, raising approximately $431.4 million. The offering included an additional 2,745,000 shares purchased by underwriters. This funding will support Dyne's mission to develop therapies for genetically driven neuromuscular diseases.

Read more →
DYN
Jul 22, 2026
DYNGeneral

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Dyne Therapeutics has announced the pricing of an upsized public offering of 18.3 million shares at $20.50 each, aiming to raise approximately $375 million. The offering is expected to close around July 23, 2026, pending customary conditions. Dyne is focused on developing therapies for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy.

Read more →
DYN
Jul 21, 2026
DYNGeneral

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics has announced a proposed public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering aims to support its clinical programs targeting genetically driven neuromuscular diseases. Market conditions may impact the completion and terms of the offering.

Read more →
DYN
Jul 20, 2026
DYNFDA Updates

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics announced that the FDA has accepted its Biologics License Application for z-rostudirsen, aimed at treating Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The application has been granted Priority Review, with a target action date set for January 21, 2027. The treatment showed significant improvements in dystrophin production and functional outcomes in clinical trials.

Read more →
DYN
Jun 22, 2026
DYNGeneral

Dyne Therapeutics Appoints Barry Greene to Board of Directors

Dyne Therapeutics has appointed Barry Greene to its Board of Directors as part of its strategy to transition into a commercial biotechnology company. Greene brings over 30 years of experience in the biopharmaceutical industry, which includes leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals. His expertise is expected to enhance Dyne's capabilities in delivering innovative therapies for neuromuscular diseases.

Read more →
DYN
Jun 17, 2026
DYNGeneral
▲ +6.3%on this newsshared move

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Dyne Therapeutics has expanded its debt facility with Hercules Capital, increasing its borrowing capacity by up to $400 million. This amendment includes an immediate funding of $50 million and additional funds contingent on achieving specific milestones. The company aims to leverage this capital to advance its clinical programs for Duchenne muscular dystrophy and myotonic dystrophy, with potential U.S. launches in the next two years.

Read more →
DYN
Jun 3, 2026
DYNPhases

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial for z-basivarsen, targeting myotonic dystrophy type 1 (DM1). A total of 71 participants were enrolled, with topline data expected in Q1 2027. The company aims for a potential U.S. launch in H1 2028, pending FDA approval.

Read more →

About Dyne Therapeutics, Inc.

Waltham, MA 258 employees dyne-tx.com
Headquarters1560 TRAPELO ROAD, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE
Trade the next DYN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime